secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2024-04-03T23:59:59+00:00
Accession:  0001104659-24-042695
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio FY 2023 net loss $56.2M; cash $5.8M; PD Phase III completed, AD top-line data expected April
--------------------------------------------------------------------------------

- Net loss Q4 2023 $22.2M vs $7.7M YoY; FY net loss $56.2M vs $25.3M.
- Cash and equivalents $5.8M as of Dec 31, 2023, down from $28.4M.
- R&D expenses $38.8M for FY 2023, up from $16.5M, driven by AD and PD trial costs.
- PD Phase III completed with 471 patients; AD Phase II/III fully enrolled (353 patients); top-line efficacy data expected in April 2024.
- Appointed Andrew Walsh as VP Finance in December 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/0001104659-24-042695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465924042695/tm2410669d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-042695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer